MITSUBISHI TANABE PHARMA CORPORATION

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

Phase 3

Completed

Conditions: Chronic Kidney Disease
Hyperphosphatemia
Dialysis

Interventions: Drug: MCI-196

First Posted Date: 2008-10-15

Last Posted Date: 2014-09-15

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 116

Registration Number: NCT00772382

Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: TA-7284
Drug: Placebo of TA-7284

First Posted Date: 2008-07-01

Last Posted Date: 2014-04-28

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 61

Registration Number: NCT00707954

Locations: 🇯🇵
P-One Clinic, Hachioji-city, Tokyo-to, Japan

Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: TA-650 3 mg/kg
Drug: TA-650 6 mg/kg
Drug: TA-650 10 mg/kg

First Posted Date: 2008-06-05

Last Posted Date: 2014-03-04

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 327

Registration Number: NCT00691028

A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: MP-424 (L), PEG-IFN-a-2b, RBV
Drug: MP-424(H), PEG-IFN-a-2b, RBV

First Posted Date: 2008-03-06

Last Posted Date: 2014-05-02

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 20

Registration Number: NCT00630058

Locations: 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan

Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Teneligliptin 40 mg
Drug: Teneligliptin 10mg
Drug: Teneligliptin 20 mg
Drug: Placebo

First Posted Date: 2008-03-04

Last Posted Date: 2013-05-31

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 324

Registration Number: NCT00628212

Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: MP-424 (Telaprevir)

First Posted Date: 2008-02-22

Last Posted Date: 2014-05-02

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 15

Registration Number: NCT00621296

Locations: 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

Phase 1

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: MP-424 (Telaprevir)

First Posted Date: 2008-01-11

Last Posted Date: 2014-05-01

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 10

Registration Number: NCT00591214

Locations: 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan

A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

Phase 3

Completed

Conditions: Chronic Kidney Disease
Dialysis
Hyperphosphatemia

Interventions: Drug: MCI-196
Drug: Another Phosphate binder (Sevelamer)

First Posted Date: 2007-10-12

Last Posted Date: 2014-10-02

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 632

Registration Number: NCT00542815

A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia

Phase 3

Completed

Conditions: Dialysis
Hyperphosphatemia
Dyslipidemia
Chronic Kidney Disease

Interventions: Drug: Placebo
Drug: MCI-196

First Posted Date: 2007-10-11

Last Posted Date: 2014-10-06

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 642

Registration Number: NCT00542386

Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)

Phase 2

Completed

Conditions: Coronary Artery Disease
Angina, Unstable

Interventions: Drug: Argatroban
Drug: Heparin

First Posted Date: 2007-07-30

Last Posted Date: 2012-12-05

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 140

Registration Number: NCT00508924

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy